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Background: The epidemiology of early-onset sepsis (EOS) may change over time.
Longitudinal surveillance of causative pathogens, antibiotic susceptibility patterns and
antibiotic therapy is important for optimal therapy strategies.
Objectives: To describe the incidence of culture-confirmed EOS, causative pathogens,
antibiotic susceptibility patterns and antibiotic therapy over a 23-year period.
Methods: Retrospective population-based study from a single-center neonatal intensive
care unit at Stavanger University Hospital, Norway, covering a population in South-West
Norway, during the 23-year period 1996–2018.
Results: Of 104,377 live born infants, 101 infants (0.97/1,000) had culture-confirmed
EOS; 89 with Gram positive and 12 with Gram-negative bacteria. The EOS-attributable
mortality was 6/101 (5.8%). For the three most prevalent pathogens the incidences
were; Group B streptococcus (GBS) 0.57/1,000, Escherichia coli 0.11/1,000 and viridans
group streptococci (VGS) 0.10/1,000. GBS was the most common pathogen (59/93;
63%) in infants with gestational age (GA) ≥ 28 weeks. In contrast, among extremely
preterm infants (GA <28 weeks) the incidence of E. coli infection was higher than for
GBS infection. The second most common bacterial pathogens causing EOS among
term infants were VGS. There was no change in the incidence of EOS for the entire
study period, but from 2000 to 2018 there was a mean decline in EOS by 6% per
year (95% CI 1%−10%) (p = 0.019). The incidences of GBS and E. coli did not
change during the study period. The initial empirical antibiotic regimen for EOS was in
all cases a combination of benzylpenicillin or ampicillin and an aminoglycoside, but in
21/101 (21%) of cases a broad-spectrum antibiotic was either added or substituted
this regimen. In 2/101 (2%) EOS cases, the pathogens were nonsusceptible to the
empirical antibiotic regimen. All E. coli isolates were susceptible to aminoglycosides.
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Conclusion: GBS was the most common causative pathogens in EOS, but E. coli
dominated in infants with GA <28 weeks. There was no change in the incidence of
EOS during the entire study period. The current empiric regimen with benzylpenicillin
and gentamicin provides a very high coverage for EOS in our setting.
Keywords: infection, early-onset sepsis, neonatal sepsis, antibiotic therapy, antibiotic resistance, antibiotic
susceptibility
INTRODUCTION
Early-onset sepsis (EOS) remains a major contributor to neonatal
morbidity and mortality (1). Although most EOS cases occur
in term infants, incidence and infection-attributable mortality
is higher in preterm infants, inversely related to gestational
age (GA) (2). In many countries and regions the incidence
of EOS has decreased in the past decades, in particular after
implementing effective intrapartum antibiotic prophylaxis (1, 3–
6). Among term (GA ≥ 37 weeks) and moderately preterm
infants (GA 28–36 weeks) with EOS, group B streptococci (GBS)
are the dominant pathogens identified in blood cultures (5–
7). In contrast, among extremely preterm infants (GA < 28
weeks), Escherichia coli is often the most frequently detected
pathogen (5). Patterns of other bacterial pathogens causing EOS
are less well-described.
In infants with suspected EOS, empirical antibiotic therapy
is commenced before blood culture results are available.
Longitudinal surveillance for identification of changes in
causative pathogens, clinical outcomes including mortality,
and antibiotic susceptibility is important when tailoring
optimal prevention and empiric therapy strategies (5, 8, 9).
However, data on antibiotic susceptibility is often not reported
in epidemiological studies. There is growing concern about
increasing antibiotic nonsusceptibility among pathogens
causing EOS, especially in Gram-negative pathogens where
often few therapeutic options are available (10). Increasing
nonsusceptibility rates, could potentially threaten the
effectiveness of standard empiric regimens (5, 10–12). In
the action plan to combat antibiotic resistance, the World
Health Organization calls for increased knowledge on local
epidemiology and antibiotic susceptibility patterns (9).
In this population-based study including more than 100,000
live born (LB) infants, we aimed to describe the incidence
of culture-confirmed EOS, causative pathogens, antibiotic




Stavanger University Hospital in South-West Norway is the
only hospital for a well-defined population of around 370,000
inhabitants, offering primary, secondary and tertiary obstetric
and neonatal intensive care. There have been 4,000–5,000 annual
deliveries during the last decades. All infants born in the
catchment area and who receive intravenous antibiotic therapy
for EOS have been admitted to the neonatal intensive care unit
(NICU) in Stavanger.
Study Design, Participants, and Data
Collection
This is a single-center, population-based retrospective study over
a 23-year period from January 1996 to December 2018. The
annual number of live births with a GA of ≥22 weeks during the
study period were obtained from the maternity unit. Newborn
infants with positive blood cultures obtained during the first
72 h of life were identified by the local microbiology laboratory
blood culture registry, and causative pathogens and antibiotic
susceptibility were registered. Detailed clinical information was
extracted from the medical records for all infants with culture-
confirmed EOS, including GA, birthweight (BW), symptoms and
signs of EOS, infection-attributable mortality, maximum value of
C-reactive protein (CRP), choice of antibiotics and duration of
therapy. The diagnosis of clinical chorioamnionitis was extracted
from the mother’s medical record.
Definitions, Microbiology, and Antibiotic
Therapy
EOS was defined as growth of pathogenic bacteria in a blood
culture obtained ≤72 h of life, and treatment with antibiotics
≥5 or <5 days if death occurred (1). Culture-negative EOS is
a controversial diagnosis (13), and we did not include cases
coined as culture-negative sepsis also due to lack of a uniform
consensus definition. EOS-attributable mortality was defined
as death occurring within 7 days after growth of pathogenic
bacteria in blood culture where sepsis was the assumed cause.
The incidence of EOS was defined as cases of EOS per 1,000 LB
infants. Clinical chorioamnionitis was prospectively diagnosed
by the responsible obstetrician, and for this study the clinical
diagnosis was obtained from the medical records. Cases later
diagnosed as histological chorioamnionitis were not included.
Infants were classified as symptomatic if they had signs of EOS,
and the time from birth to onset of symptoms was registered.
Blood cultures were obtained prior to initiation of antibiotic
therapy using BacT/ALERT PF Plus Aerobic Pediatric culture
bottles (BioMérieux, Inc., Durham, NC) throughout the study
period. Matrix-assisted laser desorption ionization - time-of-
flight (MALDI-TOF) mass spectrometry was introduced in 2012,
gradually replacing traditional phenotypic species identification.
Micrococci, propionibacteria, corynebacteria, or diphtheroids
grown alone in a single culture, growth of more than one
bacteria, and all coagulase-negative staphylococci (CoNS) were
considered contaminants (1). Pathogens were grouped into
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Gram-positive and Gram-negative bacteria. Viridans group
streptococci (VGS) include Streptococcus mitis and Streptococcus
alactolyticus and “Other streptococci” in this report include
Streptococcus pyogenes and Streptococcus pneumoniae. A blood
culture pathogen was defined as susceptible to an antibiotic
when the final interpretation report indicated S (susceptible)
and nonsusceptible when the report indicated R (resistant) or
I (intermediate). Antibiotic susceptibility testing followed the
guidelines from the Norwegian working group for antibiotics
(14), closely aligned with the EUCAST criteria (15).
The local empirical antibiotic regimen for EOS consisted of
ampicillin in combination with an aminoglycoside (tobramycin
or gentamicin) from 1996 to 2010, and benzylpenicillin and
gentamicin from 2011 to 2018.
Ethical Considerations
The local institutional review board and data protection officer
approved the study as a local quality improvement project that
did not need approval by the regional ethics committee.
Statistical Analyses
Data were analyzed using IBM-SPSS version 24 statistical
software (IBM, ArmonkNY, USA). Results are expressed as mean
with 95% confidence interval (CI) or median with interquartile
range (IQR), as appropriate. Differences between groups and
time periods (1996–2006 vs. 2007–2018) were analyzed with t-
test or Mann-Whitney test as appropriate for continuous data,
and the chi-square test or Fisher-exact test for categorical data.
Regression models were used to test for trends over time (linear)
where year was the continuous predictor. All tests were two-
tailed. P-values of <0.05 were considered statistically significant.
RESULTS
Incidence and Causative Pathogens
During the 23-year study period, 104,377 infants were LB. Of
these; 96,024 (92%) infants were born at term, and 8,353 (8%)
infants were born preterm before 37 weeks gestation. Among
the preterm infants, 7,890 (7.6%) had GA between 28–36 weeks
and 463 (0.4%) GA <28 weeks. There were 101 infants with
culture-confirmed EOS (Figure 1). The overall incidence of EOS,
incidence by causative pathogens and incidence for different
groups of GA are presented in Table 1 and with subgroups
in Figure 2. Most cases of EOS were among term infants;
71/101 (70%), but the incidence was higher among preterm
infants (Table 1). Compared to term infants, the incidence of
EOS in moderately preterm (GA 28–36 weeks) and extremely
preterm (GA < 28 weeks) infants were 3.9 and 24-fold
higher, respectively.
Among term and moderately preterm infants, GBS was a
more frequent cause of EOS than E. coli. In extremely preterm
infants however, there were four cases of E. coli infection and
only one GBS case (Table 1). The incidence of Gram-negative
pathogens decreased by increasing weeks of GA (OR 0.79, 95%
CI 0.69–0.89, p < 0.001). VGS was the second largest group of
pathogens with 10/101 cases (10%), predominantly occurring in
term infants (9/10).
The yearly incidence of EOS for different pathogens are shown
in Figure 3. There was no difference in the total incidence of EOS
between the two periods 1996–2006 and 2007–2018 (1.05/1,000
vs. 0.90/1,000, p = 0.49). There was no change in the incidence
during the study period for all infants with EOS or for EOS caused
by different pathogens (data not shown). However, for the period
from 2000 through 2018 analyzed separately, there was a mean
decline in the incidence of EOS by 6% per year (95%CI 1–10%) (p
= 0.019). There was no change in the incidence of EOS during the
study period for any of the GA groups when analyzed separately
(data not shown).
Clinical Characteristics and Mortality
In total, 14/101 infants with EOS had been exposed to
chorioamnionitis; 10/71 (14%) term, nomoderately preterm, and
4/8 (50%) extremely preterm infants. Among infants with EOS
exposed to chorioamnionitis, all extremely preterm infants and
7/10 term infants developed symptoms of EOS within the first
6 h of life. Overall, 95/101 (94%) infants with EOS had onset of
symptoms within the first 24 h of life. The median (IQR) time to
start of EOS-symptoms was 3.0 h (1.0, 13.0). The proportion of
infants with symptoms at birth was higher among preterm 18/30
(60%) compared to term infants 26/71 (37%), p= 0.047.
Themortality andmaximum value of CRP for different groups
of GA with EOS are shown in Table 2. Six infants with EOS
died; five of these were born preterm. The median (IQR) GA in
infants who died was 34 (26–36) weeks. The EOS- attributable
mortality was higher in infants with GA <28 weeks compared
to term infants (p = 0.025). The maximum CRP values were
higher in infants withGram-positive compared toGram-negative
EOS, p= 0.003.
Antibiotic Therapy and Susceptibility
The antibiotic regimen for EOS was in all cases a combination of
benzylpenicillin or ampicillin and an aminoglycoside. In 21/101
(21%) of cases, a broad-spectrum antibiotic was either added or
substituted later the empiric regimen. There was no change in the
number of infants given broad-spectrum antibiotics between the
periods 1996–2006 and 2007–2018.
The median (IQR) duration of antibiotic therapy for EOS
declined from 14 (10–14) days in the period 1996–2006
compared to 8 (7–10) days in the period 2007–2018 (p < 0.013).
All GBS isolates were susceptible to benzylpenicillin, and all
E. coli isolates were susceptible to both gentamicin and a third-
generation cephalosporin. No Gram-negative isolates produced
extended-spectrum beta-lactamase (ESBL). 10/11 (91%) of E. coli
isolates were nonsusceptible to ampicillin (Table 3).
Among the nine Staphylococcus aureus EOS isolates,
one isolates was nonsusceptible to both benzylpenicillin
and aminoglycosides; the combination empiric regimen
in use. Eight of nine isolates were susceptible to an
aminoglycoside. One isolate was methicillin resistant
(MRSA), but susceptible to an aminoglycoside. Six out
of nine S. aureus EOS isolates were nonsusceptible to
benzylpenicillin. All other Gram-positive EOS isolates in
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FIGURE 1 | Flowchart – Infants diagnosed with early-onset sepsis in a population-based observational study at Stavanger University Hospital, Norway, 1996–2018.
TABLE 1 | Incidence of early-onset sepsis (EOS) per 1000 live births among infants born at Stavanger University Hospital during 1996–2018.
All EOS isolates GBS Escherichia coli VGS








All N = 101 N = 60 N = 11 N = 10
N = 104,377 0.97 (0.71, 1.23) 0.57 (0.39, 0.75) 0.11 (0.03, 0.18) 0.10 (0.06, 0.19)
GA ≥ 37 weeks N = 71 N = 45 N = 3 N = 9
N = 96,024 0.74 (0.52, 0.96) 0.47 (0.31, 0.63) 0.03 (0.02, 0.09) 0.084 (0.014, 0.18)
GA 28–36 weeks N = 22 N = 14 N = 4 N = 1
N = 7,890 2.8 (1.43, 4.28) 1.8 (0.66, 3.0) 0.51 (0.01, 0.92) 0.13
GA < 28 weeks N = 8 N = 1 N = 4 N = 0
N = 463 17.8 (6.2, 29.4) 2.2 8.2 (0.13, 16.3)
Incidence; case per 1,000 live births.
GA, Gestational age, median (IQR); GBS, group B streptococci; VGS, viridans group streptococci.
this study were uniformly susceptible to benzylpenicillin.
The overall non-susceptibility rate to the current empirical
regimen benzylpenicillin and gentamicin was 2/101
(2%) (Table 3).
DISCUSSION
This study reports the epidemiology of EOS and antibiotic
susceptibility over more than two decades in a well-defined
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FIGURE 2 | Causative pathogens in culture-confirmed early-onset sepsis (EOS) in infants born at Stavanger University Hospital, 1996–2018. (A) GA ≥ 37 weeks. (B)
GA 28–36 weeks. (C) GA < 28 weeks. GBS, Group B Streptococci; VGS, viridans group streptococci.
FIGURE 3 | Annual incidence of early-onset sepsis (EOS) per 1,000 live born caused by all pathogens, Group B streptococci (GBS), Escherichia coli and viridans
group streptococci (VGS) during 1996-2018. GBS, Group B Streptococci; VGS, viridans group streptococci.
population in South-West Norway. Key findings are that GBS
is the most common causative pathogen in EOS, but E. coli
dominates in infants with GA <28 weeks. The incidence of
EOS remained stable for the entire study period, but with a
possible decline in incidence for the period 2000–2018 analyzed
separately. Finally, we demonstrated a low level of antibiotic
nonsusceptibility, and the current recommended empirical
antibiotic regimen (benzylpenicillin and gentamicin) continues
to have an excellent coverage for EOS in our area.
The overall incidence of EOS was 0.97/1000 LB, comparable
to reports from other epidemiological studies from Sweden (0.9)
(3), United Kingdom (0.7) (16) and the United States (0.77–
1.08) (1, 5, 17). We found a 24-fold higher incidence of EOS in
extremely preterm infants compared to term infants, a slightly
lower ratio than the 30-fold higher EOS rate reported by Stoll
et al. (5). The high rate of EOS cases in extremely preterm
infants is a reminder of the vulnerability of preterm infants,
emphasizing the importance of clinicians’ high vigilance in care
of these infants.
VGS, along with E. coli, was interestingly the second largest
group of pathogens that caused EOS, predominantly in term
infants. All infants with VGS-EOS had clinical symptoms
suggestive of sepsis, CRP levels above 10 mg/L and received
≥5 days of antibiotics, indicating a clinically relevant sepsis
episode. In many other studies, VGS are excluded as “unspecific”
(3), complicating the comparisons between studies. Stoll et al.
reported that 7/235 (3.0%) infants with EOS had growth of
VGS (5), whereas 10/862 (1.2%) infants in the 1989–2003 data
from Yale-New Haven had VGS sepsis (8). In the Yale-New
Haven data, commensal organisms such as VGS increased during
1979–1988, possible because the simultaneously rise in preterm
patient population with longer duration of NICU hospitalization
and central vascular catheters. In our study though, VGS were
almost exclusively found among term infants. VGS have also
been reported to be the cause of EOS among infants exposed to
chorioamnionitis and being asymptomatic within 6 h of age (18).
We found no change in the total incidence of EOS for the
entire 23-year study period, nor in the incidence of Gram-
positive or Gram-negative EOS. Data from Yale-New Haven
Hospital showed a decrease in EOS from 1979 to 2004, and
from 2004 to 2013 a stable incidence of around 0.9/1,000 (6). In
contrast, a recent population-based study from Sweden showed a
significant reduction in EOS incidence over the last two decades
(3). However, both studies had a baseline incidence that were
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TABLE 2 | Early-onset sepsis (EOS) attributable mortality and maximum C-reactive protein (CRP) levels among infants of different gestational age (GA) born at Stavanger
University Hospital, 1996–2018.
All cases EOS Gram-positive EOS Gram-negative EOS
Deaths/Cases (%) CRP* (mg/L) Deaths/Cases (%) CRP* (mg/L) Deaths/Cases (%) CRP* (mg/L)
All infants 6/101 (5.8%) 65 (39–110) 3/89 (3.3%) 67 (44–120) 3/12 (25%) 30 (11–62)
GA ≥ 37 weeks 1/71 (1.4%) 65 (43–122) 1/67 (1.5%) 67 (47–126) 0/4 (0%) 22 (5–39)
GA 28–36 weeks 3/22 (13%) 71 (22–99) 2/18 (11%) 65 (10–96) 1/4 (25%) 55 (17–114)
GA < 28 weeks 2/8 (25%) 45 (13–112) 0/4 (0) 92 (20–167) 2/4 (50%) 30 (10–60)
IQR, interquartile range; EOS, Early-onset sepsis; GA, gestational age.
*C-reactive protein (CRP) values are the highest values reported during the sepsis episode and presented as median and interquartile range (mg/L).
higher compared to our study. We found a significant reduction
in the total EOS incidence with a mean 6% decline per year for
the period 2000–2018. This was however not an a priori planned
analysis, and should be interpreted with caution. On the other
hand, it concurs with two multicenter studies from 2005–2014
in UK and 2002–2012 in Australian and New Zealand reporting
a decreasing trend in the incidence of EOS to 0.7/1,000 and
0.83/1,000, respectively (16, 19).
E. coli, associated with high mortality rates, caused a
substantial proportion of EOS in extremely preterm infants. We
found a stable incidence of E. coli EOS during the 23 years, in
line with other European studies (3, 16), but numbers may be too
small to detect significant changes. In contrast, US and Australian
studies (1, 5, 19–21) consistently reports higher rates of E. coli
EOS. Stoll et al. reported an increasing incidence of E. coli sepsis
when comparing surveillance data from 2015–2017 to 2006–2009
(5), with overall incidence rates of 0.4/1000 LBs and 12.1/1000
LB in infants with GA <28 weeks. The lower incidence of E. coli
EOS in European studies are usually accompanied by a higher
incidence rate of GBS, as in our study (3, 16). Yet, the incidence
of GBS in our study is comparable to other reports (1, 5, 7).
We did not find any change in incidence during these years.
Risk-based intrapartum antibiotic preventive strategies against
GBS, based on UK guidelines, were implemented in our unit in
2008 (22, 23). Limitations in the GBS prevention strategies have
been demonstrated both in risk-based and in screening-based
programs (5, 24), but the latter may be associated with a slightly
lower rate of EOS caused by GBS.
We found that the maximum CRP level in both Gram-
positive and Gram-negative bacteria were relatively low. This is
in line with other studies reporting on elevation of inflammatory
markers in EOS (25, 26), and is an important reminder for clinical
evaluation of infants at risk of EOS within a structured strategy
(4, 27).
One of the key findings in this study was that the vast
majority (98%) of EOS isolates were susceptible to the current
empirical antibiotic regimen; benzylpenicillin and gentamicin.
Although numbers are small, the Gram-negative antibiotic
nonsusceptibility rate, remained unchanged. This is comparable
to a recent study, from the USA where they found a stable
E. coli nonsusceptibility rate during 2009–2017 (10). The
nonsusceptibility rates were on the other hand substantially
higher than in our study. Our nonsusceptibility rates correlate
well-with a UK study reporting a 7% nonsusceptibility to the
TABLE 3 | Antibiotic nonsusceptibility rates in cases with early-onset sepsis at
Stavanger University Hospital, 1996–2018.
Nonsusceptible
Escherichia coli (n = 11)
• Ampicillin 10/11 (91%)
• Gentamicin 0/11 (0%)
• Third generation cephalosporin 0/11 (0%)
Staphylococcus aureus (n = 9)
• Gentamicin 1/9 (11%)
• Oxacillin (methicillin-resistant -MRSA) 1/9 (11%)
All early-onset sepsis isolates (n = 101)
• Benzylpenicillin + gentamicin (combined) 2/101 (2%)
All group B streptococci (N = 60) and all viridans group streptococci (n = 10) were
susceptible to benzylpenicillin.
empirical antibiotic regimen of benzylpenicillin and gentamicin
among 328 EOS isolates (11). Furthermore, Cailes et al. reported
a decreasing nonsusceptibility from 2005–2009 to 2010–2014,
and also a lower nonsusceptibility rate among Gram-negative
isolates causing EOS vs. late-onset sepsis. Nonsusceptibility rates
are low in Norway due to a restrictive antibiotic policy, although
increasing gentamicin nonsusceptibility of E. coli, extended-
spectrum beta-lactamase producing Gram-negative bacteria and
MRSA are increasingly found (28). This, correlates well-with
Flannery et al. findings that pathogens causing EOS in the
USA are not affected by the increasing extreme drug resistance
seen globally (10, 29). In 2011, our NICU changed from
ampicillin to benzylpenicillin as the beta-lactam backbone for
empiric EOS therapy. Ampicillin use is associated with a higher
Klebsiella pneumoniae gut colonization, including ampicillin
nonsusceptible strains (30). Our results do not support the need
for empirical use of ampicillin instead of benzylpenicillin.
Key strengths of this study are the 23-year long study
period and the strictly population-based design. The number
of infants included in our study roughly equals the total
number of births in Norway over a 2-year period. We
have complete data sets on all infants with positive blood
cultures, including antibiotic susceptibility patterns, antibiotic
use, and neonatal and maternal data for the entire study
period. The data were collected by a single researcher. The
study includes detailed maternal and neonatal information.
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We only included culture-confirmed episodes regarded as
the “gold standard” for the definition of neonatal sepsis.
There are also limitations. The data were collected from a
single-center and the findings may not be generalizable to
other countries with high antibiotic consumption driving high
antibiotic nonsusceptibility rates, settings with higher burden
of neonatal sepsis, or settings with limited resources and weak
healthcare systems. Another important limitation is the low rate
of extremely preterm infants. Albeit being in line with other
regions of Norway, it may be lower compared to countries
outside Scandinavia. Finally, there are inherent limitations with
retrospective data.
CONCLUSION
In this population-based study of EOS over 23 years, we
found that that GBS was the most common causative
pathogens in EOS, but among extremely preterm infants
E. coli dominated. We found no change in the incidence
of EOS during the whole 23-year period, but with
a possible decrease in incidence during 2000–2018.
Empirical benzylpenicillin and gentamicin in combination
provides a very high coverage for EOS pathogens in
our setting.
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